Hhlr Advisors, Ltd. I Mab Transaction History
Hhlr Advisors, Ltd.
- $3.26 Billion
- Q1 2025
A detailed history of Hhlr Advisors, Ltd. transactions in I Mab stock. As of the latest transaction made, Hhlr Advisors, Ltd. holds 5,980,568 shares of IMAB stock, worth $13.7 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
5,980,568
Previous 5,980,568
-0.0%
Holding current value
$13.7 Million
Previous $5.08 Million
3.52%
% of portfolio
0.15%
Previous 0.19%
Shares
6 transactions
Others Institutions Holding IMAB
# of Institutions
38Shares Held
13.8MCall Options Held
20KPut Options Held
13.3K-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$9.54 Million3.04% of portfolio
-
Sg Americas Securities, LLC822KShares$1.88 Million0.0% of portfolio
-
Stonepine Capital Management, LLC Bend, OR484KShares$1.11 Million0.39% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny363KShares$831,7280.0% of portfolio
-
Ubs Group Ag319KShares$729,4700.0% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $190M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...